ulmonary hypertension (PH) is a deadly disease of the lung vasculature characterized by high blood pressure in the pulmonary arteries. The World Health Organization classifies PH into 5 groups according to the underlying pathophysiology.
To this list of fundamental metabolic processes contributing to PAH, Yu et al 2 now expand on yet another: maturation of iron-sulfur (Fe-S) clusters. Fe-S clusters are assemblies of iron and sulfide in various configurations that mediate oxidation/reduction chemistry in a wide variety of enzymes. They can facilitate electron transfers and radical formation and, pertinent to the current discussion, act as sulfur donors. The latter function is critical for the generation of lipoic acid, a cofactor integral to 4 enzyme complexes in mammals: pyruvate dehydrogenase, oxoglutarate dehydrogenase, branched chain ketoacid dehydrogenase, and the H protein of the glycine cleavage system (GCSH). Mitochondrial fuel oxidation and glycine breakdown thus critically rely on proper assembly of Fe-S clusters. In 2 previous studies, the same group demonstrated that hypoxia in ECs suppresses the Fe-S cluster assembly proteins 1/2 (ISCU1/2), thereby disrupting the integrity of Fe-S cluster biogenesis, and that endothelial ISCU1/2 disruption in turns leads to PH. 9, 10 Enter now a new player: BOLA3 (BolA family member 3). Like ISCU1/2, BOLA3 is essential for the assembly of Fe-S clusters. 11 Inactivating mutations in BOLA3 cause multiple mitochondrial dysfunctions syndrome 2 (MMDS2), a severe autosomal recessive disease marked by systemic metabolic derangements including encephalopathy, seizures, high serum lactate, and nonketotic hyperglycemia (NKH). 12, 13 Other mutations in numerous other genes required for Fe-S cluster assembly (IBA57, NFU1, GLRX5, and ISCA1 and 2) are associated with other variants of MMDS, conclusively tying defects in Fe-S cluster assembly to MMDS. Interestingly, MMDS1 (NFU1 deficiency), although not (to date) MMDS2, has been linked to PH. The authors thus leverage these observations and dive deep into the role of BOLA3 in PH.
The authors first show that endothelial BOLA3 expression is strikingly downregulated in lungs from group 1 and 3 PH patients, as well as in multiple experimental models of PH. As with ISCU1/2, the authors next implicate hypoxia in the suppression of BOLA3 in ECs, in large part mediated by HIF-2α (hypoxia-inducible factor-2α; Figure) . As predicted, suppression of BOLA3 affected lipoate loading, and therefore activity, of pyruvate dehydrogenase and other lipoatecontaining dehydrogenases, as well as of GCSH. GCSH dysfunction, in turn, led to accumulation of glycine. Functionally, the authors then show in cell culture that BOLA3 deficiency promotes endothelial proliferation and vasoconstriction, hallmarks of PH. Finally, in a series of elegant in vivo experiments, the authors conclusively demonstrate that endothelium-specific suppression of BOLA3 promotes PH, whereas conversely, endothelial overexpression of BOLA3 prevents PH in a number of experimental PH models.
It thus seems quite convincing that endothelial BOLA3 deficiency can cause PH, and, in light of the profound loss of endothelial BOLA3 expression in lungs from patients with PH, that the pathway is highly relevant to the human disease. But how, mechanistically, does aberrant Fe-S clustering lead to vascular dysfunction? Loss of function of which of the high number of enzymes that depend on Fe-S clusters causes PH? Even if limited to lipoate-containing enzymes, which dehydrogenase is critical? Here, the authors perform a remarkable experiment: they demonstrate that feeding a diet supplemented with glycine, enough to lead to moderate hyperglycinemia, was sufficient to block the benefits of expression of BOLA3 in ECs. In other words, BOLA3 overexpression in ECs cannot protect against PH if BOLA3 is prevented from suppressing glycine levels in the lung. This is a remarkable observation and puts the blame for PH squarely on the glycine cleavage system. The equally surprising observation that oxygen consumption rates were not suppressed in BOLA3-deficient cells suggests that mitochondrial dehydrogenases were intact and is also consistent with glycine being a primary culprit.
What do we know about hyperglycinemia? Glycine encephalopathy (also known as NKH) is a metabolic disorder marked by seizures, mental retardation, and frequent neonatal death caused by apnea. Classically, NKH is caused by genetic variants in the P and T proteins of the glycine cleavage system, with at least 1 example in the H protein (GCSH). As noted previously, GCSH is lipoylated and thus sensitive to Fe-S cluster integrity. Consistent with this, mutations in BOLA3 and other genes of Fe-S cluster assembly, including GLRX5, NFU1, ISCA1/2, and IBA57, have been linked to NKH. And, as noted previously, at least NFU1 mutations have also been linked to PH. The study from Yu et al 2 thus strongly implicates glycine accumulation in PH pathogenesis. But is glycine accumulation sufficient to drive PH? If so, then one would predict that other causes of NKH (ie, not related to Fe-S assembly), such as mutations in lipoate synthesis genes LIAS or LIPT2, would also cause PH. However, such associations have not been reported. Interestingly, 1 case of a patient with LIPT1 aberrancy and PH has been reported, but this patient did not have hyperglycinemia or aberrant GCSH lipoylation.
14 These observations suggest that other impacts of Fe-S cluster assembly must also be at play, including on other dehydrogenases, heme biosynthesis, iron homeostasis, or tRNA modifications critical for protein synthesis. In short, although glycine accumulation may well be involved in the pathogenesis of PH, it is unlikely to be sufficient.
How would glycine accumulation mechanistically contribute to PH? This question is left largely unanswered. The authors speculate on the need to preserve intracellular glycine pools during hypoxia, but this does not address how glycine pools affect PH. Could glycine metabolism link to that of arginine and nitric oxide somehow? Or could glycine accumulation prevent serine-to-glycine flux via product inhibition of serine hydroxyl methyl transferase, thereby depriving the cell of one-carbon pool replenishment? Glycine is also a key backbone component of purines, so could high glycine promote nucleotide synthesis and endothelial proliferation? The mechanism by which high glycine contributes to PH remains entirely unknown.
Like all interesting stories, more questions are raised than answered. Why is the pulmonary vascular bed affected differently than systemic vessels by these genetic modifications? Are defects in glycine catabolism special to this case, or generalizable to other causes of PH, including secondary causes, as suggested by the hypoxic experiments? Why do mutations in different Fe-S assembly factors cause different diseases, not all of which include PH? How does the current work relate to the increasingly well-established suppression of pyruvate dehydrogenase in PH? And to the defective BMPR2 signaling seen in most familial cases of PAH? These questions are worth answering, because despite the drugs available for the clinical management of PH patients, PH remains incurable, with ≈50% mortality at 5 years. The work by Ye et al 2 significantly expands our knowledge, continues to support the notion that metabolic dysfunction in ECs is one of the primary drivers of PH pathophysiology, and perhaps suggests that targeting glycine catabolism of ECs might offer a new therapeutic strategy. 
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